WBC

Babson College's Center for Women's Entrepreneurial Leadership, in conjunction with Women Business Collaborative and Wells Fargo Launch Series on the Fundamentals of Capital

Retrieved on: 
Tuesday, January 17, 2023
Capital, Babson College, WBC, Interview, Woman, Capital structure, Segment, Entrepreneurial leadership, Wells Fargo, Management

WASHINGTON, Jan. 17, 2023 /PRNewswire/ -- Babson College's Center for Women's Entrepreneurial Leadership, Women Business Collaborative (WBC), and Wells Fargo are thrilled to announce a collaboration that will produce educational resources for women entrepreneurs and businesswomen.

Key Points: 
  • WASHINGTON, Jan. 17, 2023 /PRNewswire/ -- Babson College's Center for Women's Entrepreneurial Leadership, Women Business Collaborative (WBC), and Wells Fargo are thrilled to announce a collaboration that will produce educational resources for women entrepreneurs and businesswomen.
  • The Fundamentals of Capital modules and interviews provide women entrepreneurs and businesswomen with tools to learn about how capital is structured.
  • "Judith Goldkrand, Wells Fargo Commercial Banking National Women's Segment leader, shares, "Wells Fargo is deeply committed to empowering women business owners.
  • We're proud to partner with Women Business Collaborative and Babson College to develop this valuable learning series and help women make informed capital decisions to support their business growth and financial success."

LBank Exchange Listed Weber (WBC) on January 1, 2023

Retrieved on: 
Tuesday, January 3, 2023
Ecosystem, IPFS, WBC, WEPL-LP, Growth, Semantic Web, Feedback, Blockchain, Internet, Psychological effects of Internet use, Cryptocurrency, DAPP

Internet City, Dubai--(Newsfile Corp. - January 3, 2023) - LBank Exchange, a global digital asset trading platform, listed Weber (WBC) on January 1, 2023.

Key Points: 
  • Internet City, Dubai--(Newsfile Corp. - January 3, 2023) - LBank Exchange, a global digital asset trading platform, listed Weber (WBC) on January 1, 2023.
  • For all users of LBank Exchange, the WBC/USDT trading pair was officially available for trading at 8:00 UTC on January 1, 2023.
  • Its native token Weber (WBC) was listed on LBank Exchange at 8:00 UTC on January 1, 2023, to further expand its global reach and help it achieve its vision.
  • There's also a decentralized and distributed cloud system called Werverage that processes various contents and data of the Weber platform.

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Retrieved on: 
Sunday, December 11, 2022
Enzyme, Flow cytometry, WBC, Primate, ASH, AML, Hematocrit, Toxicity, COVID-19, Basophil, Observation, Bilirubin, Form 10-K, Gemstone, NHP, Reticulocyte, Safety, Cancer, Antibody-drug conjugate, CD123, Workforce, Biosimilar, Society, Pandemic, Hematology, Therapy, Diffusion, ADC, Control, Venetoclax, Male, PALO, Patient, Azacitidine, Failure, Bone marrow, Myelocyte, 8-K, Toxic shock syndrome, Drug Quality and Security Act, Survival, Lymphocyte, IND, KSPI, Fine chemical, Pharmaceutical industry, Risk management, Gemtuzumab ozogamicin, Bayer

PALO ALTO, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology (ASH) Annual Meeting 2022.

Key Points: 
  • VIP943 combines the unique payload class of kinesin spindle protein inhibitors (KSPi) with a proprietary legumain-cleavable linker.
  • “I am truly excited about the preclinical results for VIP943 and our proprietary payload and linker technology presented at ASH,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx.
  • The in vivo AML mouse model results also showed improved efficacy and survival for VIP943 in combination with venetoclax and azacitidine.
  • Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022

Retrieved on: 
Tuesday, December 6, 2022
Allergy, Hives, Skin temperature, WBC, ET, UCT, Fever, Consultant, Kinetics, Research, COVID-19, Wound healing, GUF, Judgement, B cell, Omalizumab, Phase II, Cancer, Skin, Knowledge, Risk, Hematology, Senior, Therapy, Annual report, Metabolic pathway, Hypersensitivity, Temperature, Dress, SCF, Exercise, Immune system, Disease, Safety, Patient, KIT, Cell, Intellectual property, Tryptase, Inflammation, AES, Angioedema, Form 10-K, Common, Survival, ID, Cold urticaria, Aluminium, Pharmaceutical industry, Tanning (leather), Vaccine, Copper

HAMPTON, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced new data from the Company’s open label Phase 1b clinical trial of barzolvolimab in patients with antihistamine refractory chronic inducible urticarias are being presented at the GA²LEN Global Urticaria Forum (GUF) held in Berlin, Germany. These diseases, which are often severe and debilitating, can significantly impact patients’ lives. Barzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity.All 9 of 9 (100%) cold urticaria patients who received a 1.5 mg/kg single full dose of barzolvolimab experienced a complete response as assessed by provocation testing, including 4 of 4 patients with omalizumab refractory disease. This cohort was added to the Phase 1b trial in patients with chronic inducible urticaria after Celldex previously reported a 95% complete response rate in July 2021 in patients with antihistamine-refractory cold urticaria and symptomatic dermographism who received a single 3.0 mg/kg dose of barzolvolimab.

Key Points: 
  • ET -
    HAMPTON, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced new data from the Company’s open label Phase 1b clinical trial of barzolvolimab in patients with antihistamine refractory chronic inducible urticarias are being presented at the GA²LEN Global Urticaria Forum (GUF) held in Berlin, Germany.
  • A randomized, double-blind, placebo-controlled, multi-dose Phase 2 subcutaneous study of barzolvolimab is currently enrolling patients with both cold urticaria and symptomatic dermographism.
  • Cold Urticaria 1.5 mg/kg intravenous cohort oral presentation: “Cold urticaria patients achieve complete response with 1.5 mg/kg barzolvolimab”
    10 patients received a single intravenous infusion of barzolvolimab at 1.5 mg/kg.
  • Additional Presentations: Encore presentations reviewing previously presented data from the Phase 1b study in chronic spontaneous urticaria and on wound healing are also being presented at GUF.

Clinical Evaluation Concludes PixCell Medical's HemoScreen is an Accurate and Easy-to-Use Point-of-Care Analyzer for Psychiatric Companion Diagnostics

Retrieved on: 
Thursday, December 15, 2022
Patient, CBC, South London and Maudsley NHS Foundation Trust, Research, Viscoelasticity, FDA, Psychiatry, Quality of life, Journal, Nathan Kline Institute for Psychiatric Research, WBC, Schizophrenia, Complete blood count, Journal of Psychiatric Research, National Association Medical Staff Services, Medical device, Clozapine

Since many psychiatric patients show severe needle anxiety, this protocol has a significant negative effect on both Clozapine treatment enrollment and adherence.

Key Points: 
  • Since many psychiatric patients show severe needle anxiety, this protocol has a significant negative effect on both Clozapine treatment enrollment and adherence.
  • The clinical evaluation comprising 226 Clozapine-treated patients has found strong correlations between the standard lab venous method and HemoScreen's capillary and venous assays.
  • This study, which is being published in the Journal of Psychiatric Research, concluded HemoScreen to be a viable fit for finger-prick companion diagnostics, with the potential to substantially enhance treatment enrollment and adherence.
  • "HemoScreen offers a portable, quick and accurate alternative to the current venous blood non-portable methods of clozapine monitoring, and from a single drop of either capillary or venous blood.

Cell Counting Global Market Report 2022: Applications of Cell Counting in Personalized Medicine Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 6, 2022
Biotechnology, Genetics, Health, Stem Cells, Laboratory, International Society for Stem Cell Research, HIV, Software, Conditional sentence, International Society, ARV, Patient, Prevalence, Cell, Cancer, Research, Death, BD (company), Alzheimer's disease, D, COVID-19, Growth, Consumables, Informatics, WBC, Stem cell, Complete blood count, USD, Pharmaceutical industry

The global cell counting market size is expected to reach USD 15.46 billion by 2030, according to this report., expanding at a CAGR of 8.21% from 2022 to 2030.

Key Points: 
  • The global cell counting market size is expected to reach USD 15.46 billion by 2030, according to this report., expanding at a CAGR of 8.21% from 2022 to 2030.
  • The increasing prevalence of these diseases has surged clinical research activities, consequently propelling the demand for cell counting instruments and consumables.
  • Government initiatives working to promote the development of cell therapeutics, wherein cell counting plays an imperative role, are also expanding growth prospects for the market.
  • One of the promising technological advancements in differential cell counting is the ability to recognize blasts, immunoplatelet counting, detection of blasts, and reticulocyte fractions and stem cell counting with greater accuracy.

OSF HealthCare joins Chicago ARC and a venture collaborative of leading organizations to tackle healthcare inequities for region's underserved populations

Retrieved on: 
Wednesday, December 7, 2022
OSF, Champaign–Urbana metropolitan area, Thomas Jefferson University, Frazier Healthcare Partners, OSF HealthCare, World Business, Conditional sentence, UIUC, Economic development, Partnership, Acceleration, Sheba Medical Center, Research, Substance use disorder, Jefferson Health, Illinois Institute of Technology, ARC, Health equity, University of Illinois Urbana-Champaign, Research Park at the University of Illinois Urbana-Champaign, Multimedia, Bop TV, University, Medical Center, WBC, Education, Hospital, Health, Today, Newsweek, Organization, Health insurance, Pharmaceutical industry, Management, Airline, Americare, M.B.A, Collaboration

CHICAGO and PEORIA, Ill., Dec. 7, 2022 /PRNewswire/ -- New Chicago ARC partners OSF HealthCare, Americare Senior Living, University of Illinois at Urbana-Champaign (UIUC), Insight Hospital and Medical Center, and Illinois Tech join a collaborative of leading organizations to create an ambitious partnership to tackle healthcare inequities through market-driven, community-informed solutions and attraction of startups that will support the region's underserved populations.

Key Points: 
  • By doing so, the partners will create replicable models to improve access, quality, cost of care, and address health inequities and social determinants of health.
  • "The Chicago ARC and its network of leading partner organizations creates the ideal way for Sheba to translate our learnings and best practices to the U.S. healthcare market.
  • The Chicago ARC is on a mission to accelerate tomorrow's healthcare solutions to those in need today.
  • Chicago ARC builds upon the proven ARC model (Accelerate, Redesign, Collaborate) of Sheba Medical Center a Newsweek Top-10 Global Hospital.

Cell Counting Market Report 2022: Growing Biotechnology and Biopharmaceutical Industries Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 30, 2022
Health, Biotechnology, Culture, RBC, Growth, WBC, Revenue, Immune system, Prevalence, Hematocrit, Conditional sentence, Hospital, Patient, Cell counting, USD, Interphase, Blood, AIDS, Virus, Cancer, Research, Cell, Hemocytometer, Cell biology, Application, Plasma, Fine chemical, Vaccine, Microscope

The global cell counting market size is expected to reach USD 15.38 billion by 2030 according to a new study.

Key Points: 
  • The global cell counting market size is expected to reach USD 15.38 billion by 2030 according to a new study.
  • Cell counting is vital in calculating cell concentrations for plating in culture, evaluating the results of cell isolation processes, and detecting cell viability.
  • In life science, cell counting methods such as hemocytometers, automated cell counting, and electrical resistance are the most precise ways to count cells.
  • The publisher has segmented the Cell Counting market report based on product, application, end use and region:
    Cell Counting, Product Outlook (Revenue - USD Billion, 2018 - 2030)

Melbourne International Coffee Expo Returned With Great Success After Two-Year Hiatus

Retrieved on: 
Tuesday, November 29, 2022
COVID-19, Culture, Taste, WBC, World Barista Championship, La Prima Espresso Company, Milk, Creativity, Coffee, MICE, Drink

SYDNEY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- According to Espresso Company, supplier of thebest coffee machines Australia-wide, the Melbourne International Coffee Expo (MICE) provided a wealth of networking opportunities for the coffee community.

Key Points: 
  • SYDNEY, Nov. 30, 2022 (GLOBE NEWSWIRE) -- According to Espresso Company, supplier of thebest coffee machines Australia-wide, the Melbourne International Coffee Expo (MICE) provided a wealth of networking opportunities for the coffee community.
  • This year, Melbourne Coffee Week was a celebration of the resilience of the industry and coffee lovers alike, with a week-long celebration of all things coffee and culminating in the tradeshow.
  • Guest roasters included green bean coffee importers and Jibbi Little, who is regarded as the latte art queen in the specialty coffee community.
  • Espresso Company explains that the competition focuses on promoting excellence in coffee, advancing the barista profession and engaging a worldwide audience.

Women Business Collaborative Announces Appointment of Shelly Kapoor Collins and Gerri Mason Hall to Board of Directors

Retrieved on: 
Tuesday, November 22, 2022
Office of Inspector General (United States), Research, Woman, WBC, PC Advisor, UNCF, Workplace, NetApp, Sodexo, The Excellence in Diversity Awards, Multimedia, Yangan Masonic Hall, Amtrak, Movement, Partner, Pharmaceutical industry, Management

WASHINGTON, Nov. 22, 2022 /PRNewswire/ --Women Business Collaborative (WBC) today announced the appointment of Shelly Kapoor Collins and Gerri Mason Hall to its Board of Directors.

Key Points: 
  • WASHINGTON, Nov. 22, 2022 /PRNewswire/ --Women Business Collaborative (WBC) today announced the appointment of Shelly Kapoor Collins and Gerri Mason Hall to its Board of Directors.
  • "We are incredibly excited to welcome Shelly and Gerri to our Board," said Edie Fraser, CEO of WBC.
  • "I'm honored to be asked to join the board of Women Business Collaborative," said Collins.
  • The Women Business Collaborative (WBC) is an unprecedented alliance of more than 75 women's business organizations and hundreds of business leaders building a movement to achieve equal position, pay, and power for all women in business.